In recent years, more and more real-world studies have found that some EGFR-TKI-resistant NSCLC patients could indeed benefit from PD-1/PD-L1 antibody combined with chemotherapy, although anti-PD-1/PD-L1 monotherapy is demonstrated to be poor effective. Here, EGFR is linked to non-small cell lung carcinoma.